IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.02 per share a year ago.
All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy
IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for Oct. 24: IGC, ASM and More
IGC, SCRYY, RY, UVE and ASM have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 24, 2025.
IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago.
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.04 per share a year ago.
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.
IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock?
IGC Pharma, Inc. (IGC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, January 23, 2025, at 1:00 pm ET. During the session, IGC Pharma's management will provide insights into the Company's recent progress, including advancements in its Alzheimer's pipeline, strategic expansion into metabolic disorders, and the integration of artificial intelligence in drug discovery.
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's). The trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer's patients worldwide that also adversely impacts the quality of life for both patients and their caregivers.
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025.
What Makes IGC Pharma, Inc. (IGC) a New Buy Stock
IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline
POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders.
